Abstract: The present invention relates to the field of (vector) vaccines, and especially to novel promoter sequences, expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.

Abstract: The present invention provides a poxvirus-derived promoter, a vector comprising the same, a method for expressing a transgene using the promoter, and use of the vector in the prevention or treatment of a disease. A promoter according to the present invention can be used for induction of strong expression of a transgene.

Abstract: A cell modification device, comprising a centrifugation chamber with at least one cell modifying surface with a normal vector having an angle of 135?45° to the rotational axis of the centrifugation chamber, wherein the centrifugation chamber comprises at least one input/output port and the cells to be modified are immobilized at the cell modifying surfaces by the rotation of the centrifugation chamber at 2 to 2000 g. In an embodiment, the device is used as a point-of-care and/or portable device. Further, the present disclosure describes software that, when executed by a processor, causes the device to perform the disclosed functions.

Abstract: The subject invention pertains to delivering a polynucleotide into a target cell, particularly, into the nucleus of the target cell. The method comprises the steps of contacting the polynucleotide with the cell and applying pressure on the polynucleotide and the cell in a manner that forces the polynucleotide into the cell. The pressure can be between about 0.1 Pa to about 50 Pa; whereas, the polynucleotide is contacted with the cell at a concentration of between about 0.1 ?M and about 100 ?M. The method can be practiced for cells in culture or cells in vivo.

Abstract: The instant disclosure relates to the use of engineered proteins such as Cas9, Cpf1, TALE and Zinc finger proteins attached with a viral integrases, recombinase, or transposase in order to deliver a DNA sequence of interest (or gene of interest) to a targeted site in a genome of a cell or organism. The use of a Cas9 that is inactive for its function in cutting DNA will allow the use of Cas9 proteins ability to target DNA by the use of RNA guides without causing DNA breaks as intended in other systems for homologous recombination. The use of zinc finger proteins or TALE (engineered proteins that bind specific sequences of DNA) attached to the viral integrase or the recombinase is also disclosed. The system may be used for laboratory and therapeutic purposes. A gene of interest can be included in a cell with a gene lacking the ability to produce its gene product to recover the normal gene product in the cell (e.g. gene product may be a protein or specialized RNA).

Abstract: The present invention provides for a genetically modified host cell capable of producing isopentenol and/or 3-methyl-3-butenol, comprising (a) an increased expression of phosphomevalonate decarboxylase (PMD) (b) an increased expression of a phosphatase capable of converting isopentenol into 3-methyl-3-butenol, (c) optionally the genetically modified host cell does not express, or has a decreased expression of one or more of NudB, phosphomevalonate kinase (PMK), and/or PMD, and (d) optionally one or more further enzymes capable of converting isopentenol and/or 3-methyl-3-butenol into a third compound, such as isoprene.

Abstract: Compositions and methods for producing hydrocarbons such as aldehydes, alkanes, and alkenes are described herein. Certain hydrocarbons can be used in biofuels.

Abstract: This invention provides recombinant cells and methods for producing terpenes and terpenoids by increasing production or accumulation or both of isoprenoid precursors thereof.

Abstract: Disclosed are whole-cell catalysts, methods of making the whole-cell catalysts, and methods of using the whole-cell catalysts to produce steviol glycosides.

Abstract: The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.

Abstract: A method of diagnosing bacterial vaginosis (BV) in a female subject including: (a) obtaining an appropriate sample from the subject; and (b) detecting the presence of at least one of 2-hydroxyisovalerate (2HV) and ?-hydroxybutyrate (GHB) in the sample.

Abstract: The present disclosure provides methods in which adherent cells are treated with small molecules, cultured, lysed, and then analyzed by mass spectrometry to measure the activities of endogenous enzymes. The implementation of this method relies on the use of surfaces that are nanopatterned with cell adhesion ligands to mediate cell attachment and a peptide that is a substrate for the desired enzyme activity in the lysate.

Abstract: Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation.

Abstract: A technique relates to separation of a mixture. A nano-deterministic lateral displacement (nanoDLD) array is configured to separate the mixture in a fluid. A feedback system is configured to control a velocity of the fluid through the nanoDLD array. The feedback system is configured to control the velocity of the fluid to separate one or more entities in the mixture.

Abstract: Methods are provided for differential biosynthetic labeling of RNA, including identification of cell type-specific programs of gene expression. The methods and compositions of the invention allow detection and/or purification of RNAs with precise spatial and temporal resolution. In various embodiments of the invention, the methods are applied to animal cells, including cell lines, stem cells, selected lineages of organisms, and the like.

Abstract: Assays can be used to detect mutations found in neoplasms of the pancreas, as well as for other neoplasms and other uses. Nucleic acids can be captured from body fluids such as cyst fluids. Thousands of oligonucleotides can be synthesized in parallel, amplified and ligated together. The ligated products can be further amplified. The amplified, ligated products are used to capture complementary DNA sequences, which can be analyzed, for example by massively parallel sequencing.

Abstract: Provided herein are devices, systems, and methods for conducting nucleic acid amplification. The devices, systems, and methods are suited for portability, rapid operation, low power consumption, integrated operation, and remote monitoring.

Abstract: Systems and methods for plasmonic heating by combined use of thin plasmonic film-based 2D and 3D structures and a light-emitting diode (LED) for nucleic acids amplification through fast thermal cycling of polymerase chain reaction (PCR) are described.

Abstract: Disclosed herein are methods of extracting genetic material from a diverse population of one or more types of microbes in a sample. Microbes can be prokaryotes or eukaryotes and may include bacteria, archaea, fungi, protozoa, helminths, parasites, viruses, phages, and others. Extraction may be from a single sample and subsequent identification may be through a molecular method such as qPCR, PCR, RFLP, SSCP, allele specific PCR, targeted sequencing, pull down sequencing, whole shotgun sequencing, or other methods.

Abstract: Primer pair, kit and method for detecting Ehrlichia Canis are disclosed. The primer pair includes a forward primer and a reverse primer, and the kit includes the primer pair and a probe. The forward primer has a sequence of SEQ ID NO: 1, the reverse primer has a sequence of SEQ ID NO: 2, and the probe has a sequence of SEQ ID NO: 3.

Abstract: Certain embodiments are directed to a point-of-care (POC) microfluidic biochip for rapid, highly sensitive and specific pertussis diagnosis. The POC biochip can be used in various venues such as physician's office, schools, hospitals, and low-resource settings so that rapid prevention and treatment of pertussis can be achieved. The POC biochip based pertussis diagnosis is low-cost and does not rely on any specialized instrument, but offers comparable sensitivity to real-time PCR.

Abstract: The invention discloses methods and apparatuses for the detection and diagnostics of genetic alterations/mutations in a target sample, which may be a solid tissue or a bodily fluid. A reference sample is also acquired, and the target and reference samples are replicated into multiple target and reference replicates. The replicates are sequenced, and the sequence data is analyzed based on a statistical test. The statistical test compares the measurements between the target and reference replicates at respective allelic indices. True positive calls are then made based on the results of the statistical testing, and the desired genetic alterations/mutations are identified at the base-pair level. The invention may be used for diagnostics related to cancer, auto-immune disease, organ transplant rejection, genetic fetal abnormalities and pathogens.

Abstract: Provided is a chip process of gene synthesis, and the process comprises incorporating the whole procedure, which comprises amplifying oligonucleotides and assembling the oligonucleotides into a gene in parallel, onto a single chip. A specific mismatch endonuclease is also used in the process to establish an error repair system in gene synthesis, and the error rate is decreased to about 0.19 mismatched bases/kb. The high-throughput, high-fidelity and low-cost chip process of gene synthesis provided in the present invention can meet the requirements of gene synthesis and the optimization and screening of protein expression on a large scale at the frontier of life sciences such as synthetic biology, genomics, and systems biology.

Abstract: Provided herein are methods for template-dependent multiple displacement amplification (tdMDA) that preferably use 5? blocked pentamer primers.

Abstract: The present disclosure provides methods and systems for assaying the presence of a target nucleic acid molecule in a sample having or suspected of having the target nucleic acid molecule. A method of assaying the presence of the target nucleic acid molecule comprises facilitating the flow of the sample through at least one nanopore in a membrane disposed adjacent or in proximity to an electrode that is adapted to detect a current or change thereof upon movement of a complex having the target nucleic acid molecule coupled to the complexing moiety through the at least one nanopore. Next, the current or change thereof is measured with the electrode. The complex in the sample is detected from the current or change thereof, thereby assaying the presence of the target nucleic acid molecule in the sample.

Abstract: The present disclosure provides methods and systems for assaying the presence of a target nucleic acid molecule in a sample having or suspected of having the target nucleic acid molecule. A method of assaying the presence of the target nucleic acid molecule comprises facilitating the flow of the sample through at least one nanopore in a membrane disposed adjacent or in proximity to an electrode that detects a current or current change upon movement of the target nucleic acid molecule through the nanopore. The target nucleic acid molecule, if present, can have a tag coupled at a terminal end thereof that increases a dwell time of the target nucleic acid molecule in the nanopore. The presence of the target nucleic acid molecule in the sample is assayed based on an increase in dwell time of the target nucleic acid molecule from measurements of the current or current change.

Abstract: Provided are compositions, methods and systems for determining the sequence of a template nucleic acid using a polymerase-based, sequencing-by-binding procedure. An examination step involves monitoring the interaction between a polymerase and template nucleic acid in the presence of one or more nucleotides. Identity of the next correct nucleotide in the sequence is determined without incorporation of any nucleotide into the structure of the primer by formation of a phosphodiester bond. An optional incorporation step can be used after the examination step to extend the primer by one or more nucleotides, thereby incrementing the template nucleotides that can be examined in a subsequent examination step. The sequencing-by-binding procedure does not require the use of labeled nucleotides or polymerases, but optionally can employ these reagents.

Abstract: A method of sequencing a nucleic acid such as DNA or RNA is provided.

Abstract: Aspects of the present invention include analyzing nucleic acids from single cells using methods that include using tagged polynucleotides containing multiplex identifier sequences.

Abstract: A method for detecting a target nucleic acid, comprising: (a) contacting a nucleic acid sample comprising a target nucleic acid, comprising a first portion and a second portion, with: (i) a detection probe, wherein the detection probe is labeled with a labeling substance and comprises a nucleic acid sequence that forms a stem-loop structure and having a 5? protruding end or a 3? protruding end that is capable of hybridizing to the second portion, and (ii) a capture probe comprising a nucleic acid sequence capable of hybridizing to the first portion, wherein the capture probe is immobilized to a substrate, under conditions to form a target nucleic acid-detection probe-capture probe complex by hybridizing the second portion to the detection probe and hybridizing the first portion to the capture probe; (b) ligating a first end of the detection probe with an end of the target nucleic acid and ligating a second end of the detection probe with an end of the capture probe; and (c) detecting the labeling substance of

Abstract: Provided herein are systems and methods for identifying cell-specific differentiation markers. In particular, provided herein are systems and methods for generating induced pluripotent cells (IPS) from human cells, differentiating the IPS into differentiated cells, and identifying differentiation specific markers.

Abstract: Methods are provided for identifying T cell receptors that specifically bind a particular antigenic target and can be used as therapeutics against disease.

Abstract: Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.

Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.

Abstract: Method of detection or diagnosis of abnormal gene expression in an individual comprising determining in a sample from the individual the presence or absence of a chromosome structure in which two separate regions of the gene have been brought into close proximity, to thereby detect or diagnose whether the individual has abnormal gene expression.

Abstract: The present invention provides methods and compositions involving epigenetic and gene expression signatures and their association with Sjögren's syndrome.

Abstract: The invention relates generally to an allele on human chromosome 9 associated with increased risk for coronary heart disease and the use or detection of such an allele in determining whether a human has an increased risk for coronary heart disease. In one aspect, the invention relates to methods for detecting a predisposition or propensity or susceptibility for coronary heart disease in a human, comprising detecting the presence of an allele on human chromosome 9 that is associated with an increased risk for coronary heart disease in a human. Disclosed are methods and compositions for determining whether a person carries an allele associated with increased risk for coronary atherosclerosis by determining whether the person has an RA-CHR9 allele, such as by determining whether the person has an RA-CHR9 allele-associated single nucleotide polymorphism (SNP). The invention also relates to kits for detecting the presence of an allele on chromosome 9 associated with an increased risk for coronary heart disease.

Abstract: Described herein are biomarkers for HPV-associated pre-cancers and cancers such as cervical cancer and cervical intraepithelial neoplasia. The RNA binding protein (RBP) and long-noncoding RNA (lnc-RNA) biomarkers can be detected and used to diagnose HPV-associated pre-cancers and cancers. In addition, early diagnosis of HPV-associated pre-cancers and cancers can facilitate therapeutic intervention in patients, particularly in the pre-cancer stage which can delay or prevent progression to cancer.

Abstract: This document provides methods and materials involved in assessing cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) having ER?/PgR?/HER2? cancer cells is likely to have a favorable or unfavorable outcome and/or is likely to respond a cancer treatment that includes a PD-1 inhibitor and/or PD-L1 inhibitor in combination with a JAK2 inhibitor are provided. Methods and materials involved in treating mammals having ER?/PgR?/HER2? cancer (e.g., ER?/PgR?/HER2? breast cancer) by administering a PD-1 inhibitor and/or PD-L1 inhibitor in combination with a JAK2 inhibitor also are provided.

Abstract: Described herein are probes useful to detect gene copy number alterations of genes characteristic/indicative of cutaneous T cell lymphoma (CTCL), such as CTCL with blood involvement, including probes specific to genes amplified or deleted in cutaneous T cell lymphoma (CTCL), such as CTCL with blood involvement; methods of detecting a (one or more) genetic abnormality, such as one or more gene copy number alteration (GCNA), characteristic/indicative of cutaneous T cell lymphoma (CTCL), such as CTCL with blood involvement, in a biological sample obtained from an individual; and methods of determining if an individual has cutaneous T cell lymphoma (CTCL), such as CTCL with blood involvement, or is likely to develop cutaneous T cell lymphoma (CTCL) with blood involvement.

Abstract: The present disclosure provides method for determining an immune response score (irScore), the method comprising: determining a number of differentially expressed genes that have are implicated in anti-tumor immune cell signaling/activation; determining a number of differentially expressed genes that are implicated in immunosuppression, wherein the irScore=X(low, medium, or high), wherein X is the number of differentially expressed genes that are implicated in anti-tumor immune cell signaling/activation, and wherein low refers to 1-4 differentially expressed genes that are implicated in immunosuppression, medium refers to 5-9 differentially expressed genes that are implicated in immunosuppression, and high refers to 10 or more differentially expressed genes that are implicated in immunosuppression.

Abstract: The present invention relates to a method for classifying a prostate cancer in a subject, the method comprising the steps of a) determining a gene expression level or gene expression pattern of the genes F3 and IGFBP3 in a sample from the subject and b) classifying the tumor by comparing the gene expression level determined in a) with a reference gene expression of the same genes in reference patients known to have a high risk or low risk tumor respectively. In addition the invention relates to a method for determining prognosis of a subject diagnosed with prostate cancer, a method for making a treatment decision for a subject diagnosed with prostate cancer and a solid support or a kit for classifying a tumor in a subject diagnosed with prostate cancer.

Abstract: The present invention relates to methods and systems for assessing the overall risk of a human female subject for developing a breast cancer phenotype. In particular, the present invention relates to combining clinical risk assessment and genetic risk assessment to improve risk analysis.

Abstract: There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.

Abstract: Primers, probes and kits for detection and lineage differentiation of influenza B virus strains are provided. Also provided are the corresponding assays and methods.

Abstract: Disclosed are a one-stop treatment method for breaking a nucleic acid by means of a transposase, and a reagent. The method of the present invention comprises the following steps: conducting random breaking of a nucleic acid by using a transposase-embedded complex, the transposase-embedded complex comprising a transposase and a first adaptor comprising a transposase identification sequence; adding a first reagent to conduct treatment, so as to break an absorption effect of the transposase to a target sequence of the nucleic acid; adding a second reagent to conduct treatment, so as to weaken the influence of the first reagent on a follow-up enzyme-catalyzed reaction; and conducting a PCR reaction by using a product generated after the second reagent treatment as a template component, so as to obtain a PCR product of a broken nucleic acid segment whose two ends are connected to adaptors.

Abstract: Compositions comprising C5 and C6 monosaccharides and low levels of undesirable impurities, such as compounds containing sulfur, nitrogen, or metals, are disclosed.

Abstract: The disclosed technology includes a mounting enclosure having a replaceable insert panel used to mount an apparatus used in a melting furnace. The replaceable insert panel may be accessed and removed from a rear open end of the mounting enclosure to allow replacement without having to access the interior of the furnace.

Abstract: The present invention relates to a high speed steel with a chemical composition that comprises, in % by weight: 0.6-2.1 C 3-5 Cr 4-14 Mo max 5 W max 15 Co 0.5-4 V, balance Fe and impurities from the manufacturing of the material, which steel is powder metallurgically manufactured and has a content of Si in the range of 0.7<Si?2.

Abstract: A decarburized self-piercing rivet is provided that can join dissimilar sheets of material while reducing the likelihood of forming cracks during the riveting process. The decarburized self-piercing rivet has requisite hardness and column strength to pierce the sheets of material and also has a ferrite layer that improves ductility and performance of the rivet. The increase ductility reduces the likelihood of cracks forming during the riveting process. A manufacturing process is also provided that austentizing and decarburizes the rivet simultaneously in a salt pot furnace to reduce the need for any post-austentizing localized heat treatments.